A planned interim analysis of the global, Phase 3 REZILIENT3 trial has demonstrated that zipalertinib (CLN-081/TAS6417) combined with platinum-based chemotherapy achieved a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone as first-line treatment for patients with EGFR exon 20 insertion (ex20ins)–mutant advanced or metastatic non-squamous NSCLC. Based on these results, the Independent Data Monitoring Committee has recommended unblinding the study, and the sponsoring companies plan to pursue regulatory approval in the United States.

Clinical Takeaway

The REZILIENT3 trial demonstrated a significant PFS benefit with zipalertinib combined with chemotherapy in the first-line setting for patients with EGFR exon 20 insertion–mutant NSCLC, a population historically associated with poor responses to standard EGFR tyrosine kinase inhibitors and limited treatment options.

Drug Profile & Mechanism

  • Drug name: Zipalertinib (also known as CLN-081 / TAS6417)
  • Drug class: Oral investigational small molecule tyrosine kinase inhibitor
  • Mechanism of action: A next-generation, irreversible EGFR inhibitor designed to inhibit EGFR variants harboring exon 20 insertion mutations while sparing wild-type EGFR
  • Administration: Oral
  • Regulatory status: Investigational; not currently approved by any health regulatory authority. The FDA has accepted a separate NDA for zipalertinib in previously treated locally advanced or metastatic EGFR ex20ins–mutant NSCLC, with a PDUFA target action date of February 27, 2027. The first-line combination evaluated in REZILIENT3 remains investigational.
  • Developers: Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics

Target Population

  • Tumor type: Non-squamous non-small cell lung cancer (NSCLC)
  • Molecular profile: EGFR exon 20 insertion (ex20ins) mutations
  • Disease stage: Locally advanced or metastatic
  • Treatment history: Previously untreated (first-line setting)
  • Patient demographics: Adults (≥18 years)

Study Design

  • Trial name: REZILIENT3 (NCT05973773)
  • Phase: Phase 3
  • Design: Randomized, multicenter, open-label, controlled global trial
  • Enrollment: 285 adults with previously untreated locally advanced or metastatic non-squamous NSCLC harboring EGFR ex20ins mutations
  • Treatment arms:
    • Experimental: Zipalertinib + pemetrexed + carboplatin or cisplatin
    • Control: Pemetrexed + carboplatin or cisplatin
  • Current status: Interim analysis completed; the Independent Data Monitoring Committee (IDMC) has recommended unblinding based on interim results; the trial will continue to follow participants for ongoing efficacy and safety assessment

Endpoints

  • Primary endpoint: Progression-free survival (PFS) by blinded independent central review (BICR) according to RECIST v1.1
  • Secondary endpoints: Overall survival (OS), investigator-assessed PFS, objective response rate (ORR), duration of response (DOR), disease control rate (DCR), intracranial efficacy, safety, pharmacokinetics, and patient-reported outcomes/quality of life

Efficacy Outcomes

  • At the planned interim analysis, zipalertinib + platinum-based chemotherapy demonstrated a statistically significant improvement in PFS compared with chemotherapy alone
  • The PFS improvement was also deemed clinically meaningful by the trial investigators and sponsoring companies
  • The IDMC reviewed the interim data and recommended unblinding the study based on the interim results
  • Specific PFS values (e.g., median PFS, hazard ratio, confidence intervals) have not yet been publicly disclosed at the topline results stage

Safety

  • The safety profile of zipalertinib in combination with platinum-based chemotherapy was described as manageable
  • Detailed adverse event data, including rates and grades of specific toxicities, have not yet been released as part of the topline announcement
  • Ongoing follow-up in the trial will continue to characterize the long-term safety profile of the combination regimen

Key Clinical Implications

✔ EGFR exon 20 insertion mutations represent a distinct and historically difficult-to-treat molecular subgroup in NSCLC; these positive Phase 3 data may signal a meaningful advance in first-line management for this population.

✔ Zipalertinib’s selective targeting of EGFR ex20ins mutations differentiates it from earlier-generation EGFR inhibitors, which have shown limited efficacy against this mutational variant.

✔ The combination of zipalertinib + platinum-based chemotherapy meeting its primary PFS endpoint supports its potential as a new first-line treatment option, pending full data disclosure, regulatory review, and approval.

✔ The IDMC recommendation to unblind the study based on the interim analysis represents an important milestone for the REZILIENT3 program.

✔ The sponsors plan to discuss the REZILIENT3 findings with the FDA and pursue U.S. regulatory approval for the first-line combination; oncology clinicians should monitor for further regulatory updates and detailed efficacy and safety data.

Bottom Line

The Phase 3 REZILIENT3 trial has met its primary endpoint, demonstrating that zipalertinib combined with platinum-based chemotherapy delivers a statistically significant and clinically meaningful improvement in progression-free survival over chemotherapy alone in patients with previously untreated, EGFR exon 20 insertion–mutant advanced or metastatic non-squamous NSCLC. With a manageable safety profile and an IDMC recommendation to unblind, Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics plan to discuss the findings with the FDA and pursue U.S. regulatory approval for the first-line combination. Full results from REZILIENT3 are planned for submission to an upcoming international medical conference. These results represent a potentially significant step forward for a patient population with substantial unmet clinical need.

Sources: